Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells (Q34404833)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

0 references

1 reference

based on heuristic

inferred from title

Daniel A Vallera

1

object named as

Daniel A Vallera

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Bin Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Michelle K Gleason

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Seunguk Oh

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Louis M Weiner

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Dan S Kaufman

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Valarie McCullar

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jeffrey S Miller

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Michael R Verneris

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

23 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Cancer Biotherapy and Radiopharmaceuticals

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

274-282

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Use of allogeneic NK cells for cancer immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Innate or adaptive immunity? The example of natural killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Regulation of human NK-cell cytokine and chemokine production by target cell recognition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

The emerging role of EpCAM in cancer and stem cell signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Nuclear signalling by tumour-associated antigen EpCAM

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

CD44 and EpCAM: cancer-initiating cell markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

EpCAM (CD326) finding its role in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

BiTEs: bispecific antibody constructs with unique anti-tumor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

6 July 2018

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

27 October 2018

Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

27 October 2018

Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

27 October 2018

When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

27 October 2018

Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

27 October 2018

CD107a as a functional marker for the identification of natural killer cell activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

27 October 2018

TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

27 October 2018

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209492

27 October 2018

EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23611188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/23611188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23611188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced

1 reference

https://pubmed.ncbi.nlm.nih.gov/23611188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23611188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer stem cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23611188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

On the abundance of EpCAM on cancer stem cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23611188

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1089/CBR.2012.1329

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34404833&oldid=1871133055"